Biogen News & Analysis
3 articles
Market Mood
Apellis (APLS) Stock Rating Downgraded After Biogen Acquisition
Roth/MKM downgraded Apellis Pharmaceuticals (APLS) following Biogen's acquisition, citing concerns over competitive pressures. This action reflects broader market sentiment regarding APLS's growth prospects in the wake of the acquisition. Specific data points and projections were not included in the downgrade, leading to uncertainty among investors. The market will be closely monitoring APLS's response and performance in the coming quarters, impacting stock movements and investor confidence.
Read More
Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal
Cantor Fitzgerald has downgraded Apellis Pharmaceuticals (APLS) following Biogen's recent acquisition. This decision reflects potential market implications for APLS shares amidst Biogen's active strategic moves. The downgrade is a response to shifts in market sentiment influenced by M&A activities. Investors may want to monitor how this impacts APLS's trading volumes and price movements in the near term.
Read More
Biogen Reports Positive Phase 2 Results for Lupus Drug: Potential Market Impact
Biogen announced positive results from its Phase 2 clinical trial for a lupus skin drug. The study indicated significant efficacy in treating the condition, although specific metrics on improvement were not provided. The positive outcomes could potentially influence market perceptions regarding Biogen’s pipeline and future drug approvals. The implications for market sentiment and Biogen's stock performance may be notable as a result.
Read More